Vertex reports early kidney drug data, boosting hopes for broad label ahead of next year's pivotal readout

Vertex Pharmaceuticals disclosed early data from its experimental kidney disease therapy inaxaplin, showing improvements on a urine-based biomarker.

The drug demonstrated positive changes in two separate patient groups, suggesting potential efficacy across a broader kidney disease spectrum.

The results have heightened expectations as the company prepares for a pivotal Phase 3 readout scheduled for next year, aiming for a wide indication label.